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What is Known Already:	Previous	guidelines	either	lacked	rigorous	evidence-	based	
processes,	did	not	engage	consumer	and	international	multidisciplinary	perspectives,	
or	 were	 outdated.	 Diagnosis	 of	 PCOS	 remains	 controversial	 and	 assessment	 and	
management	 are	 inconsistent.	 The	 needs	 of	 women	 with	 PCOS	 are	 not	 being	
	adequately	met	and	evidence	practice	gaps	persist.
Study Design, Size, Duration:	International	evidence-	based	guideline	development	en-
gaged	professional	societies	and	consumer	organizations	with	multidisciplinary	experts	
and	 women	 with	 PCOS	 directly	 involved	 at	 all	 stages.	 Appraisal	 of	 Guidelines	 for	
Research	and	Evaluation	(AGREE)	II-	compliant	processes	were	followed,	with	extensive	
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1  | WHAT DOES THIS ME AN FOR 
ADOLESCENTS AND WOMEN WITH PCOS?
This	 guideline	 aims	 to	 optimize	 evidence-	based,	 consistent	 care	
that	meets	the	needs	and	 improves	the	quality	of	 life	of	women	
with	 PCOS.	 The	 guideline	 and	 translation	 program	were	 devel-
oped	with	full	consumer	participation	at	all	stages,	targeting	areas	
and	 outcomes	 of	 priority	 for	 women	 with	 PCOS.	 The	 aim	 is	 to	
support	 women	 and	 their	 health	 care	 providers	 to	 optimize	 di-
agnosis,	 assessment	and	management	of	PCOS.	There	 is	an	em-
phasis	on	partnership	 in	care	and	empowerment	of	women	with	
PCOS.	 Personal	 characteristics,	 preferences,	 culture	 and	 values	










gagement	 informed	 guideline	 scope	 and	 priorities.	 Engaged	 international	 society-	
nominated	 panels	 included	 pediatrics,	 endocrinology,	 gynecology,	 primary	 care,	
reproductive	 endocrinology,	 obstetrics,	 psychiatry,	 psychology,	 dietetics,	 exercise	




narrative	 reviews.	 Evidence-	based	 recommendations	were	developed	 and	 approved	
via	consensus	voting	within	the	five	guideline	panels,	modified	based	on	international	
feedback	and	peer	review,	with	final	recommendations	approved	across	all	panels.
Main Results and the Role of Chance:	The	evidence	in	the	assessment	and	management	
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2  | INTRODUC TION
Polycystic	 ovary	 syndrome	 (PCOS)	 is	 the	 most	 common	 endo-
crinopathy	affecting	 reproductive	aged	women,	with	a	prevalence	
of	 between	 8%	 to	 13%	depending	 on	 the	 population	 studied	 and	
definitions	used.1,2	PCOS	 is	 complex	with	 reproductive,	metabolic	
and	psychological	features.1,2	Clinical	practice	in	the	assessment	and	
management	 of	 PCOS	 is	 inconsistent,	 with	 key	 evidence	 practice	
gaps,	whilst	women	 internationally	 have	 highlighted	 delayed	 diag-
nosis	and	dissatisfaction	with	care.3-5	Current	guidelines	either	are	
limited	in	breadth,	do	not	follow	rigorous	best	practice	in	develop-
ment,	 have	 not	 involved	 consumers,	 or	 are	 outdated,6-10	 resulting	
in	inconsistent	guidance	for	clinicians	and	women	alike.	To	address	
these	identified	gaps,	here	we	summarize	the	development	process	
and	 recommendations	 from	 the	 first	 international	 evidence-	based	
guideline	 for	 the	 assessment	 and	management	 of	 PCOS,	 bringing	
extensive	 consumer	 engagement	 and	 international	 collaboration	




This	 comprehensive	 evidence-	based	 guideline	builds	 on	prior	
high	quality	guidelines	and	culminates	 from	a	 rigorous,	AGREEII-	
compliant,	 evidence-	based	 guideline	 development	 process.	 It	
provides	 a	 single	 source	 of	 international	 evidence-	based	 recom-
mendations	to	guide	clinical	practice	with	the	opportunity	for	ad-
aptation	 in	 relevant	 health	 systems.	 Together	 with	 an	 extensive	




with	 co-	designed	 resources	 to	 upskill	 health	 professionals	 and	
empower	women	with	 PCOS,	with	 an	 integrated	 comprehensive	
evaluation	program.








Assessment,	 Development,	 and	 Evaluation	 (GRADE)	 framework	
covering	 evidence	 quality,	 feasibility,	 acceptability,	 cost,	 imple-









GDG	 including	 consumers.	 They	 refer	 to	 overall	 interpretation	
and	practical	application	of	the	recommendation,	balancing	ben-










The	 GRADE	 of	 the	 recommendation	 is	 determined	 by	 the	
GDG	based	on	comprehensive	structured	consideration	of	all	el-
ements	of	 the	GRADE	 framework,4	 including	desirable	effects,	









ber	 and	 design	 of	 studies	 addressing	 the	 outcome;	 judgments	
about	the	quality	of	the	studies	and/or	synthesized	evidence,	such	
as	 risk	 of	 bias,	 inconsistency,	 indirectness,	 imprecision,	 and	 any	












The	recommendation	 table	 (Table	3)	applies	 the	category,	descrip-
tive	terms,	GRADE	of	the	recommendations	and	the	quality	of	the	
evidence.	 The	 full	 guideline	 is	 available	 at	 https://www.monash.
edu/medicine/sphpm/mchri/pcos.	The	 full	version	of	 the	guideline	
outlines	 the	 clinical	 need	 for	 the	 question,	 the	 clinical	 question,	
the	 evidence	 summary,	 the	 recommendation	 and	 practice	 points	
and	 a	 summary	 of	 the	 justification	 developed	 by	 the	GDGs	 using	
the	 GRADE	 framework,	 refined	 by	 extensive	 international	 peer	
	review.	The	comprehensive	evidence	reviews,	profiles	and	GRADE	
frameworks	 supporting	 each	 recommendation,	 can	 be	 found	 
at	 https://www.monash.edu/medicine/sphpm/mchri/pcos	 in	 the	
Supplementary	 Technical	 Reports.	 The	 peer	 review	 feedback,	 
administrative	 report	 on	 guideline	 development	 and	 disclosure	 of	
interest	 process	 and	 declarations	 can	 be	 found	 at	 https://www.
monash.edu/medicine/sphpm/mchri/pcos.	 Here	 we	 present	 the	
clinical	 topic	 area	 recommendations	 and	 practice	 points	 (Table	3).	
This	summary,	the	full	guideline	and	technical	reports	are	supported	
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multidisciplinary	clinical	expertise,	consumer	preferences	and	struc-
tured	 review	by	 the	 five	GDGs.	Detailed	methods	 for	 stakeholder	
engagement	 and	 guideline	 development	 can	 be	 found	 at	 https://
www.monash.edu/medicine/sphpm/mchri/pcos.	The	guideline	pro-


















screened,	 assessed	 and	managed	 and	 health	 professionals	 should	








and	 anovulatory	 infertility,	 gonadotrophins	 are	 second	 line.	 In	 the	
absence	of	 an	absolute	 indication	 for	 IVF,	women	with	PCOS	and	
anovulatory	 infertility,	could	be	offered	 IVF	third	 line	where	other	
ovulation	induction	therapies	have	failed.
The	 combined	 effects	 of	 the	 provision	 of	 a	 single	 source	 of	
evidence-	based	 recommendations	 and	 comprehensive	 international	
translation	and	dissemination	program	will	amplify	impact	of	the	guide-
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assessment	 and	management	 of	 PCOS	 and	will	 augment	 the	 health	
literacy	and	self-	management	of	PCOS	health	consumers.	The	guide-








engagement,	 health	 literacy	 enhancing	 tools,	 comprehensive	 PCOS	





through	 the	 provision	 of	 timely	 and	 accurate	 diagnosis,	 accessible	
evidence-	based	 information	 and	 improved	multi-	disciplined	 support.	
Ultimately,	this	initiative	may	serve	as	an	exemplar	for	international	col-
laborative	engagement	and	healthcare	impact.	Key	elements	included	
extensive	 collaboration,	 broad	 stakeholder	 representation	 including	






1. The	 Australian	 National	 Health	 and	 Medical	 Research	 Council	
(NHMRC)	 through	 the	 funded	 Centre	 for	 Research	 Excellence	 in	
Polycystic	 Ovary	 Syndrome	 (APP1078444)	 and	 the	 members	 of	
this	 Centre	 who	 coordinated	 this	 international	 guideline	 effort.
2. Our	partner	organizations	which	co-funded	the	guideline:	
•	 American	Society	for	Reproductive	Medicine	(ASRM)
•	 European	 Society	 of	 Human	 Reproduction	 and	 Embryology	
(ESHRE)
3. Our	collaborating	and	engaged	societies	and	consumer	groups:	





































•	 Victorian	 Assisted	 Reproductive	 Technology	 Association	
(VARTA)
Other	 relevant	 organizations	 are	welcome	 to	 partner	 in	 guideline	
translation	once	approved.
CONFLIC T OF INTERE S T
Disclosures	of	conflicts	of	interest	were	declared	at	the	outset	and	
updated	 throughout	 the	 guideline	 process,	 aligned	 with	 NHMRC	
guideline	 processes.	 Full	 details	 of	 conflicts	 declared	 across	 the	
guideline	development	groups	are	available	at	https://www.monash.
edu/medicine/sphpm/mchri/pcos/guideline	 in	 the	 Register	 of	 dis-
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consumer,	 translation,	or	 international	advisory	board	members	or	
members	of	 the	evidence	 synthesis	 and	 translation	 team,	 contrib-
uted	 to	 the	 manuscript,	 prioritizing	 clinical	 questions,	 discussing	
recommendations	until	voting	and	consensus,	responses	to	external	
peer	 review	and	 approval	 of	 the	 final	 recommendations	 across	 all	
GDGs.
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